Antiangiogenic active immunotherapy
CA 2480079 C · Owner: Galban Rodriguez, Ernesto · Inventors: Musachio Lasa, Alexis; Vazquez Blomquist, Dania Marcia; Fernandez Molina, Luis Enrique
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Application of oligonucleotide and polypeptide sequences of molecules of the family , of the vascular permeability factor (VPF) their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which , course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis acute and chronic inflammatory , processes infectious diseases, autoimmune diseases diabetic and newborn retinopathies, organ transplant rejection macular degeneration, neovascular glaucoma hemangioma, and angiofibroma, among others.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 2003 and granted July 30, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.